Prospective Trial Shows Precision Medicine Benefits in Cancer Treatment

A prospective clinical trial showed that establishing a molecular portrait of a cancer patient can improve survival by identifying targetable mutations.

Results showed that 33 percent had improved progression-free survival following a comprehensive genomic analysis, and 62 percent of patients demonstrated disease control, according to researchers at the Gustave Roussy Cancer Campus, which conducted the trial. The study was presented at the Molecular Analysis for Personalised Therapy conference.

The trial enrolled 1,110 patients with various solid tumors between November 2011 and March 2016, and excluded patients with well-established actionable drug targets, such as EGFR mutations in lung cancer or HER2-positive breast cancer.